Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.
The MHRA produces over 95 per cent of the World Health Organization’s (WHO) biological standards.
List of Field Safety Notices from 6 October to 10 October 2025.
The MHRA’s Interim Executive Director of Science and Research writes in The British Medical Journal on the approval of the UK’s first new UTI antibiotic in nearly 30 years, and the wider challenge of tackling antibiotic resistance.
Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.
